44 Milton Avenue
Alpharetta, GA 30009
United States
866 620 8655
https://www.virios.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 4
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Gregory Duncan | Chairman & CEO | 566,92k | N/D | 1965 |
Dr. William L. Pridgen M.D. | Founder & Director | 35k | N/D | 1961 |
Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer | 364,94k | N/D | 1956 |
Mr. Ralph D. Grosswald M.P.H. | Senior Vice President of Operations | 274,69k | N/D | 1969 |
Ms. Carol Duffy Ph.D. | Chief Scientific Advisor | N/D | N/D | N/D |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
L'ISS Governance QualityScore di Virios Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.